EAPH mit kompletter Neubewertung - 500 Beiträge pro Seite
eröffnet am 06.06.13 16:16:14 von
neuester Beitrag 22.08.18 14:16:36 von
neuester Beitrag 22.08.18 14:16:36 von
Beiträge: 15
ID: 1.182.631
ID: 1.182.631
Aufrufe heute: 0
Gesamt: 5.860
Gesamt: 5.860
Aktive User: 0
ISIN: US2777741057 · WKN: A1CUUH · Symbol: EAPH
0,0000
USD
0,00 %
0,0000 USD
Letzter Kurs 23.03.24 Nasdaq OTC
Werte aus der Branche Pharmaindustrie
Wertpapier | Kurs | Perf. % |
---|---|---|
1,5100 | +75,79 | |
0,7500 | +50,00 | |
12,950 | +32,55 | |
5,3500 | +32,10 | |
0,7630 | +26,53 |
Wertpapier | Kurs | Perf. % |
---|---|---|
3,8500 | -16,12 | |
7,5000 | -16,67 | |
1,9000 | -18,80 | |
1,4600 | -27,00 | |
3,6400 | -38,62 |
Hallo liebe OTC Trader,
bin heute mal mit einer Position bei EAPH rein. Die haben gestern Abend HammerNews rausgebracht. Schon jetzt sind 0,10$ locker möglich...
Easton Pharmaceuticals, Inc. Announces Its Entrance into the Medical Marijuana Sector
Print
Easton Pharmaceuticals, Inc. (PL) (USOTC:EAPH)
Intraday Stock Chart
Today : Thursday 6 June 2013
Easton Pharmaceuticals, Inc. (OTC: EAPH), a specialty pharmaceutical company that designs, develops, and markets a premium array of topically-delivered therapeutic healthcare products, today announced its initiatives to enter into the Medical Marijuana Sector in both the U.S. and Canadian Markets.
As the company searches for new avenues to generate revenues and enhance its business model, Easton Pharmaceuticals, Inc. is retaining the services of a third party consultants to assist the company with submitting applications with the intent of opening small boutique clinics in both the Canadian and American markets which includes various provinces and states starting in Michigan and California, two marijuana "friendly" states for medicinal marijuana.
Michigan created a Medical Marijuana Program (MMMP), a state registry program where state law provides protections for the medical use of marijuana and allows participants to legally possess, use, buy and grow medical marijuana as will various Provinces in Canada once a national law presently being reviewed is passed.
Easton intends on using the services of qualified third parties to obtain licenses and assist with the setting up of a highly regulated and controlled small clinic with the to supply patients who have obtained a valid medical prescription. Such clinics would need to be strictly inspected on a regular basis in order that it meets all government standards. Easton and others in the industry are awaiting regulations and the approval by both the Canadian and United States governments, but is in the application process in certain states and provinces. Easton Pharmaceuticals is also in the process of developing other OTC herbal products specifically designed for this sector.
Although “Viorra” and other products possessing Easton’s reformulated transdermal delivery system is and will continue to be the main focus for the company and it’s initiatives, Easton Pharmaceuticals has entered the medical marijuana sector due to the growing acceptance by the public, all levels of governments and the revenue potential it can generate
John Adams, President of Easton Pharmaceuticals commented, "With thousands of people in the nearby state of Michigan and various Canadian provinces and jurisdictions to follow, requiring relief from various ailments and illnesses that only the use of medicinal marijuana can provide relief for, Easton has chosen to participate in this industry that has slowly over the last few years received recognition for its medicinal benefits. The United States congress was to have made a final decision approving the use of medical marijuana in limited ways, but recently adjourned the final decision for later in the year."
According to the Long Beach Business Journal in their article titled "The Business of Medical Marijuana" the medical cannabis industry alone was worth about 1.7 billion in 2011, according to a report by the financial news firm See Change Strategy. That figure could reach nearly $9 billion nationwide in five years, as the federal government in the United States clears the way for more states to likely legalize marijuana for medicinal purposes.
One of marijuana's greatest advantages as a medicine is its remarkable safety. It has little effect on major physiological functions. There is no known case of a lethal overdose. On the basis of animal models, the ratio of lethal to effective dose is estimated as 40,000 to 1. By comparison, the ratio is between 3 and 50 to 1 for secobarbital, and between 4 and 10 to 1 for ethanol. Marijuana is also far less addictive and far less subject to abuse than many drugs now used as muscle relaxants, hypnotics, and analgesics. The chief legitimate concern is the effect of smoking on the lungs. Cannabis smoke carries more tars and other particulate matter than tobacco smoke. But the amount smoked is much less, especially in medical use, and once marijuana is an openly recognized medicine, solutions may be found such as vaporization, tinctures, extracts and oils. At present, the greatest danger in medical use of marijuana is its illegality, which imposes much anxiety and expense on suffering people, forces them to bargain with illicit drug dealers, and exposes them to the threat of criminal prosecution.
About Easton Pharmaceuticals Inc
Toronto-based Easton Pharmaceuticals is a specialty pharmaceutical company that designs, develops, and markets a premium array of topically-delivered therapeutic healthcare products, focused on skin and circulatory conditions that impact a large and expanding number of consumers including health issues related to male and female sexual dysfunction, scar and stretch marks, cellulite and varicose veins, the world market for these conditions is in excess of $10 billion.
The company's updated proprietary gel formulation is an innovative and unique transdermal delivery system. Easton Pharmaceuticals’ flagship product, VIORRA, is an over-the-counter aid for the treatment to restore and improve vaginal moisture and elasticity which has a very positive effect on women’s sexual desire and arousal, FSAD (Female Sexual Arousal Disorder) the world market for these female conditions are in excess of $2 billion. VIORRA is a topical, daily-use product classified by the FDA as containing Generally Recognized as Safe ingredients.
For More Information Visit
http://www.ashleybiomedical.com & http://www.eastonpharma.com
Safe Harbor
This news release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (The "Act"). In particular, when used in the preceding of discussion, the words "pleased," "plan," "confident that," "believe," "expect," or "intent to" and similar conditional expressions are intended to identify forward-looking statements within the meaning of the Act and are subject to the safe harbor created by the Act. Such statements are subject to certain risks and uncertainties and actual results could differ materially from those expressed in any of the forward-looking statements. Such risks and uncertainties include, but are not limited to, market conditions, general acceptance of the company's products and technologies, competitive factors, the ability to successfully complete additional or adequate financing and other risks and uncertainties as stated in the company's financial reports and filings.
John Adams, President/CEO
Contact:
Easton Pharmaceuticals Inc.
Tel: +1(416) 619-0291
Tel: +1(347) 284-0192
Media and Investor Relations: info@ashleybiomedical.com, info@lamindustries.com
http://ih.advfn.com/p.php?pid=nmona&article=57869147
bin heute mal mit einer Position bei EAPH rein. Die haben gestern Abend HammerNews rausgebracht. Schon jetzt sind 0,10$ locker möglich...
Easton Pharmaceuticals, Inc. Announces Its Entrance into the Medical Marijuana Sector
Easton Pharmaceuticals, Inc. (PL) (USOTC:EAPH)
Intraday Stock Chart
Today : Thursday 6 June 2013
Easton Pharmaceuticals, Inc. (OTC: EAPH), a specialty pharmaceutical company that designs, develops, and markets a premium array of topically-delivered therapeutic healthcare products, today announced its initiatives to enter into the Medical Marijuana Sector in both the U.S. and Canadian Markets.
As the company searches for new avenues to generate revenues and enhance its business model, Easton Pharmaceuticals, Inc. is retaining the services of a third party consultants to assist the company with submitting applications with the intent of opening small boutique clinics in both the Canadian and American markets which includes various provinces and states starting in Michigan and California, two marijuana "friendly" states for medicinal marijuana.
Michigan created a Medical Marijuana Program (MMMP), a state registry program where state law provides protections for the medical use of marijuana and allows participants to legally possess, use, buy and grow medical marijuana as will various Provinces in Canada once a national law presently being reviewed is passed.
Easton intends on using the services of qualified third parties to obtain licenses and assist with the setting up of a highly regulated and controlled small clinic with the to supply patients who have obtained a valid medical prescription. Such clinics would need to be strictly inspected on a regular basis in order that it meets all government standards. Easton and others in the industry are awaiting regulations and the approval by both the Canadian and United States governments, but is in the application process in certain states and provinces. Easton Pharmaceuticals is also in the process of developing other OTC herbal products specifically designed for this sector.
Although “Viorra” and other products possessing Easton’s reformulated transdermal delivery system is and will continue to be the main focus for the company and it’s initiatives, Easton Pharmaceuticals has entered the medical marijuana sector due to the growing acceptance by the public, all levels of governments and the revenue potential it can generate
John Adams, President of Easton Pharmaceuticals commented, "With thousands of people in the nearby state of Michigan and various Canadian provinces and jurisdictions to follow, requiring relief from various ailments and illnesses that only the use of medicinal marijuana can provide relief for, Easton has chosen to participate in this industry that has slowly over the last few years received recognition for its medicinal benefits. The United States congress was to have made a final decision approving the use of medical marijuana in limited ways, but recently adjourned the final decision for later in the year."
According to the Long Beach Business Journal in their article titled "The Business of Medical Marijuana" the medical cannabis industry alone was worth about 1.7 billion in 2011, according to a report by the financial news firm See Change Strategy. That figure could reach nearly $9 billion nationwide in five years, as the federal government in the United States clears the way for more states to likely legalize marijuana for medicinal purposes.
One of marijuana's greatest advantages as a medicine is its remarkable safety. It has little effect on major physiological functions. There is no known case of a lethal overdose. On the basis of animal models, the ratio of lethal to effective dose is estimated as 40,000 to 1. By comparison, the ratio is between 3 and 50 to 1 for secobarbital, and between 4 and 10 to 1 for ethanol. Marijuana is also far less addictive and far less subject to abuse than many drugs now used as muscle relaxants, hypnotics, and analgesics. The chief legitimate concern is the effect of smoking on the lungs. Cannabis smoke carries more tars and other particulate matter than tobacco smoke. But the amount smoked is much less, especially in medical use, and once marijuana is an openly recognized medicine, solutions may be found such as vaporization, tinctures, extracts and oils. At present, the greatest danger in medical use of marijuana is its illegality, which imposes much anxiety and expense on suffering people, forces them to bargain with illicit drug dealers, and exposes them to the threat of criminal prosecution.
About Easton Pharmaceuticals Inc
Toronto-based Easton Pharmaceuticals is a specialty pharmaceutical company that designs, develops, and markets a premium array of topically-delivered therapeutic healthcare products, focused on skin and circulatory conditions that impact a large and expanding number of consumers including health issues related to male and female sexual dysfunction, scar and stretch marks, cellulite and varicose veins, the world market for these conditions is in excess of $10 billion.
The company's updated proprietary gel formulation is an innovative and unique transdermal delivery system. Easton Pharmaceuticals’ flagship product, VIORRA, is an over-the-counter aid for the treatment to restore and improve vaginal moisture and elasticity which has a very positive effect on women’s sexual desire and arousal, FSAD (Female Sexual Arousal Disorder) the world market for these female conditions are in excess of $2 billion. VIORRA is a topical, daily-use product classified by the FDA as containing Generally Recognized as Safe ingredients.
For More Information Visit
http://www.ashleybiomedical.com & http://www.eastonpharma.com
Safe Harbor
This news release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (The "Act"). In particular, when used in the preceding of discussion, the words "pleased," "plan," "confident that," "believe," "expect," or "intent to" and similar conditional expressions are intended to identify forward-looking statements within the meaning of the Act and are subject to the safe harbor created by the Act. Such statements are subject to certain risks and uncertainties and actual results could differ materially from those expressed in any of the forward-looking statements. Such risks and uncertainties include, but are not limited to, market conditions, general acceptance of the company's products and technologies, competitive factors, the ability to successfully complete additional or adequate financing and other risks and uncertainties as stated in the company's financial reports and filings.
John Adams, President/CEO
Contact:
Easton Pharmaceuticals Inc.
Tel: +1(416) 619-0291
Tel: +1(347) 284-0192
Media and Investor Relations: info@ashleybiomedical.com, info@lamindustries.com
http://ih.advfn.com/p.php?pid=nmona&article=57869147
Dürfte aber vor allem auch ein Pushding sein. Tradingtechnisch interessant wenn es heute Stärke zeigt und bei ggf aussichtsreichen Intradaychart ist es eine Überlegung wert.
Überflüssig zu sagen, dass man sowas nicht heiraten sollte - es sei dann man hat Geld zu verschenken.
Überflüssig zu sagen, dass man sowas nicht heiraten sollte - es sei dann man hat Geld zu verschenken.
Definitiv, da gebe ich dir Recht...ein guter Zock für Zeitraum 10 Tage denke ich...auch aufgrund der Eckdaten deutlich solider als manch anderer OTC Zock...eine gute Basis ist da...da sollte noch etwas gehen
Antwort auf Beitrag Nr.: 44.802.523 von chris1808 am 06.06.13 20:48:10Der Tagesverlauf spricht eher dagegen, klasisch abverkauft:
Wenns Stärke gezeigt hätte, wäre es für mich ein Kaufgrund gewesen so sieht es aber düster aus, ich wär hier sehr vorsichtig. Sollten morgen wider erwarten die Hochs von heute anvisiert werden, kann man immer noch rein.
Wenns Stärke gezeigt hätte, wäre es für mich ein Kaufgrund gewesen so sieht es aber düster aus, ich wär hier sehr vorsichtig. Sollten morgen wider erwarten die Hochs von heute anvisiert werden, kann man immer noch rein.
Wie geht es heute weiter ?
Info.
Easton Pharmaceuticals Signs Letter of Intent / NDA, Enters Into Negotiations With Private B.C. Company Who Has Received Federal License Approval on Medical Marijuana & Closes on Agreement to Engage Leading Legal Consultant
2014-02-07 09:16 ET - News Release
TORONTO, ON -- (Marketwired) -- 02/07/14
Easton Pharmaceuticals Inc. (OTC: EAPH) a specialty pharmaceutical company that owns, designs, develops, and markets an array of topically-delivered drugs and therapeutic / cosmetic healthcare products, today announces It has finalized and closed on agreement to engage a leading legal consultant on medical marijuana. Subsequent to this agreement, Easton has signed a Letter Of Intent / NDA and has entered into high level negotiations with a private company based out of British Columbia who has been approved for a medical marijuana license to grow and distribute medical marijuana throughout all of Canada.
Easton Pharmaceuticals has finalized and closed on an agreement with one of the foremost respected and knowledgeable legal experts and consulting firms in Canada towards medical marijuana. This company is to be lead project manager to draft and file an application on behalf of Easton Pharmaceuticals who will be completely responsible to be project manager and hire security firms, engineers and architects and other experts who will conform the warehouse and facilities to adhere to strict Health Canada Standards for its application.
The name and details of the legal consulting firm are being kept private for a very short period of time as a result of the company executing a letter of intent / NDA and entering into high level discussions with a British Columbia based private company who has just been approved and granted a medical marijuana license for growing and distributing throughout Canada. The introduction and the quick circumstances towards executing the letter of intent was not only unexpected, but was signed 1 day after entering into a contract with the legal consulting firm, superseding all other discussions with other companies. The B.C. private company is one of the first companies to have been approved for a license and is well respected within the industry and by health Canada. They are currently in the process of building out their facility in B.C as per their approved application with plans to apply and open other facilities to serve the greater Toronto area, North America's 4th largest city and other eastern jurisdictions in the country, which may possibly involve Easton Pharmaceuticals. The company and management believe a fair and equitable partnership agreement can be attained, apart from some details and issues. Should negotiations not result in any agreement, the company will continue with moving on its own highly detailed medical marijuana application utilizing the knowledge and expertise of its legal consultant who are currently consulting the government of Uruguay with its own marijuana laws. Negotiations and discussions are to be very fast moving, with an expected decision to be made within the next week to 10 days, followed by a formal announcement.
About Easton Pharmaceuticals
Easton Pharmaceuticals is a specialty pharmaceutical company that owns, designs, develops, and markets topically-delivered Drugs and therapeutic healthcare products, focused on Cancer and other health issues related to male and female sexual dysfunction, wound healing, pain, motion sickness, scar and stretch marks, cellulite, varicose veins and other conditions. The company's gel formulation is thought to be an innovative and unique transdermal delivery system. Easton Pharmaceuticals product "VIORRA," is an over-the-counter aid for the treatment to restore and improve vaginal moisture and elasticity which is believed to have a positive effect on women's sexual desire and arousal, FSAD (Female Sexual Arousal Disorder) the world market for these female conditions are conservatively estimated to be in excess of $2 billion. VIORRA is a topical, daily-use product classified by the FDA as containing Generally Recognized as Safe ingredients.
For More Information Visit
http://www.eastonpharma.comhttp://www.ashleybiomedical.com
Safe Harbor
This news release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (The "Act"). In particular, when used in the preceding of discussion, the words "pleased," "plan," "confident that," "believe," "expect," "possible" or "intent to" and similar conditional expressions are intended to identify forward-looking statements within the meaning of the Act and are subject to the safe harbor created by the Act. Such statements are subject to certain risks and uncertainties and actual results could differ materially from those expressed in any of the forward-looking statements. Such risks and uncertainties include, but are not limited to, market conditions, general acceptance of the company's products and technologies, competitive factors, the ability to successfully complete additional or adequate financing, government approvals or changes to proposed laws and other risks and uncertainties further stated in the company's financial reports and filings.
© 2014 Canjex Publishing Ltd. All rights reserved.
Easton Pharmaceuticals Signs Letter of Intent / NDA, Enters Into Negotiations With Private B.C. Company Who Has Received Federal License Approval on Medical Marijuana & Closes on Agreement to Engage Leading Legal Consultant
2014-02-07 09:16 ET - News Release
TORONTO, ON -- (Marketwired) -- 02/07/14
Easton Pharmaceuticals Inc. (OTC: EAPH) a specialty pharmaceutical company that owns, designs, develops, and markets an array of topically-delivered drugs and therapeutic / cosmetic healthcare products, today announces It has finalized and closed on agreement to engage a leading legal consultant on medical marijuana. Subsequent to this agreement, Easton has signed a Letter Of Intent / NDA and has entered into high level negotiations with a private company based out of British Columbia who has been approved for a medical marijuana license to grow and distribute medical marijuana throughout all of Canada.
Easton Pharmaceuticals has finalized and closed on an agreement with one of the foremost respected and knowledgeable legal experts and consulting firms in Canada towards medical marijuana. This company is to be lead project manager to draft and file an application on behalf of Easton Pharmaceuticals who will be completely responsible to be project manager and hire security firms, engineers and architects and other experts who will conform the warehouse and facilities to adhere to strict Health Canada Standards for its application.
The name and details of the legal consulting firm are being kept private for a very short period of time as a result of the company executing a letter of intent / NDA and entering into high level discussions with a British Columbia based private company who has just been approved and granted a medical marijuana license for growing and distributing throughout Canada. The introduction and the quick circumstances towards executing the letter of intent was not only unexpected, but was signed 1 day after entering into a contract with the legal consulting firm, superseding all other discussions with other companies. The B.C. private company is one of the first companies to have been approved for a license and is well respected within the industry and by health Canada. They are currently in the process of building out their facility in B.C as per their approved application with plans to apply and open other facilities to serve the greater Toronto area, North America's 4th largest city and other eastern jurisdictions in the country, which may possibly involve Easton Pharmaceuticals. The company and management believe a fair and equitable partnership agreement can be attained, apart from some details and issues. Should negotiations not result in any agreement, the company will continue with moving on its own highly detailed medical marijuana application utilizing the knowledge and expertise of its legal consultant who are currently consulting the government of Uruguay with its own marijuana laws. Negotiations and discussions are to be very fast moving, with an expected decision to be made within the next week to 10 days, followed by a formal announcement.
About Easton Pharmaceuticals
Easton Pharmaceuticals is a specialty pharmaceutical company that owns, designs, develops, and markets topically-delivered Drugs and therapeutic healthcare products, focused on Cancer and other health issues related to male and female sexual dysfunction, wound healing, pain, motion sickness, scar and stretch marks, cellulite, varicose veins and other conditions. The company's gel formulation is thought to be an innovative and unique transdermal delivery system. Easton Pharmaceuticals product "VIORRA," is an over-the-counter aid for the treatment to restore and improve vaginal moisture and elasticity which is believed to have a positive effect on women's sexual desire and arousal, FSAD (Female Sexual Arousal Disorder) the world market for these female conditions are conservatively estimated to be in excess of $2 billion. VIORRA is a topical, daily-use product classified by the FDA as containing Generally Recognized as Safe ingredients.
For More Information Visit
http://www.eastonpharma.comhttp://www.ashleybiomedical.com
Safe Harbor
This news release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (The "Act"). In particular, when used in the preceding of discussion, the words "pleased," "plan," "confident that," "believe," "expect," "possible" or "intent to" and similar conditional expressions are intended to identify forward-looking statements within the meaning of the Act and are subject to the safe harbor created by the Act. Such statements are subject to certain risks and uncertainties and actual results could differ materially from those expressed in any of the forward-looking statements. Such risks and uncertainties include, but are not limited to, market conditions, general acceptance of the company's products and technologies, competitive factors, the ability to successfully complete additional or adequate financing, government approvals or changes to proposed laws and other risks and uncertainties further stated in the company's financial reports and filings.
© 2014 Canjex Publishing Ltd. All rights reserved.
Antwort auf Beitrag Nr.: 46.401.148 von Montekaolino am 07.02.14 15:26:23 so hoffe um reges inteesse , wer weiß was und wer denkt was über diesen wert ......
bitte um rege beteiligung
dankeeeeeeeeee
bitte um rege beteiligung
dankeeeeeeeeee
Antwort auf Beitrag Nr.: 47.272.808 von medarex75 am 07.07.14 18:29:15
Es geht doch nur geduld. Wie sehen noch ganz andere kurse.
Es geht doch nur geduld. Wie sehen noch ganz andere kurse.
Bei welchem Broker handelt ihr EAPH ?
Ist hier jemand dabei ?
Info.
http://www.otcmarkets.com/news/otc-market-headline?id=708186
Easton Pharmaceuticals and BMV Medica Announces First Shipment of Gynofit To Multi-National Pharmaceutical Company, Gedeon Richter, Towards Its Purchase Order, Has Been Received For February 16th Product Launch in Puerto Vallarta, Mexico
TORONTO, ON -- (Marketwired) -- 02/03/17 -- Easton Pharmaceuticals, Inc. (OTC PINK: EAPH) announces after having received initial payment towards product purchase order from pharmaceutical multi-national Gedeon Richter's Plc subsidiary - Gedeon Richter Mexico S.A.P.I. de C.V., the first shipment of "Gynofit" bacterial vaginosis treatment has been shipped and received in Mexico in preparation of its product launch in Puerto Vallarta, Mexico for February 16th.
Gedeon Richter will be showcasing the products as it launches its marketing and sales program with a steadily increasing marketing budget over the next 3 years. Easton / BMV will provide sales figures and projections sometime in the next quarter.
"Gynofit" is a natural product treatment for women diagnosed with BV (Bacterial Vaginosis), a condition that affects nearly all women at some point in their lives and is one of the most common reasons for gynecological visits by women. In addition, Gynofit will be promoted for help in maintenance of a healthy vaginal flora. As previously announced, the agreement with Gedeon Richter Mexico S.A.P.I de C.V. provides for annual minimums in return for granting exclusivity. Gedeon Richter Plc and Gedeon Richter Mexico S.A.P.I. de C.V. has committed to a strong marketing plan for Gynofit and its success, which Easton / BMV and Gedeon Richter believe will steadily drive sales in Mexico over the next three years and beyond.
Other News
Easton Pharmaceuticals continues to move forward with its due diligence for the acquisition of revenue generating iBliss Inc., as previously announced and expects to have the transaction completed sometime in the month of February once all terms of the agreement have been agreed to and finalized.
Easton is also confirming that it has entered into negotiations towards acquiring a second revenue generating company possessing strong international sales which could coincide with the closing of iBliss and BMV Medica S.A.
Easton is also in late stage negotiations towards 2 (two) agreements with two 2 (two) medical marijuana companies, one in Jamaica and the other in the US, both expecting to potentially add significant and near term sales to Easton. Updates are expected this month or as they materialize.
Easton also confirms that late stage negotiations are continuing towards Eastons / BMV Medica's other licensed products (VS-Sense, AL-Sense). Detailed updates expected very shortly
For More Detailed Information On iBliss Visit: https://iblissvapor.com
For More Detailed Information on Gedeon Richter Plc Visit:
http://www.richter.hu/en-US/Pages/default.aspx
About Easton Pharmaceuticals
Easton Pharmaceuticals is a diversified specialty pharmaceutical company involved in various pharmaceutical sectors and other growing industries. The Company previously developed and owned an FDA-approved wound-healing drug and currently owns topically delivered drugs to treat cancer and other therapeutic products to treat various conditions that are all in various stages of development and approval. Easton has partnered with BMV Medica SA de C.V. and together, own the exclusive distribution rights in Mexico and Latin America for patented women's diagnostic and preventative care products from CommonSense of Israel, along with two generic cancer drugs, Paclitaxel and Docetaxel from BioLyse Pharma of St. Catherine's Ontario, Canada.
For More Information Visit: http://www.eastonpharmaceuticalsinc.com
http://www.bmvmedica.net
http://ecigmarkets.com
http://finance.yahoo.com/q?s=eaph
https://twitter.com/eastonpharma
Safe Harbor This news release may contain forward-looking statements or expressions within the meaning of the Private Securities Litigation Reform Act of 1995 (The "Act"). In particular, when certain words or phrases such as "hope", "positive", "anticipate," "pleased," "plan," "confident that," "believe," "expect," "possible" or "intent to" and similar conditional expressions are expressed, they are intended to identify forward-looking statements within the meaning of the Act and are subject to the safe harbor created by the Act. Such statements are subject to certain risks and uncertainties and actual results could differ materially from those expressed in any of the forward-looking statements. Such risks and uncertainties include, but are not limited to, market conditions, general acceptance of the company's products and technologies, competitive factors, the ability to successfully complete additional or adequate financing, government approvals or changes to proposed laws and other risks and uncertainties further stated in the company's financial reports and filings.
Contact Information
Evan Karras
CEO
Tel: +1(416) 619-0291
Tel: +1(347) 284-0192
Email: info@eastonpharmaceuticalsinc.com
Source: Easton Pharmaceuticals, Inc.
http://www.otcmarkets.com/news/otc-market-headline?id=708186
Easton Pharmaceuticals and BMV Medica Announces First Shipment of Gynofit To Multi-National Pharmaceutical Company, Gedeon Richter, Towards Its Purchase Order, Has Been Received For February 16th Product Launch in Puerto Vallarta, Mexico
TORONTO, ON -- (Marketwired) -- 02/03/17 -- Easton Pharmaceuticals, Inc. (OTC PINK: EAPH) announces after having received initial payment towards product purchase order from pharmaceutical multi-national Gedeon Richter's Plc subsidiary - Gedeon Richter Mexico S.A.P.I. de C.V., the first shipment of "Gynofit" bacterial vaginosis treatment has been shipped and received in Mexico in preparation of its product launch in Puerto Vallarta, Mexico for February 16th.
Gedeon Richter will be showcasing the products as it launches its marketing and sales program with a steadily increasing marketing budget over the next 3 years. Easton / BMV will provide sales figures and projections sometime in the next quarter.
"Gynofit" is a natural product treatment for women diagnosed with BV (Bacterial Vaginosis), a condition that affects nearly all women at some point in their lives and is one of the most common reasons for gynecological visits by women. In addition, Gynofit will be promoted for help in maintenance of a healthy vaginal flora. As previously announced, the agreement with Gedeon Richter Mexico S.A.P.I de C.V. provides for annual minimums in return for granting exclusivity. Gedeon Richter Plc and Gedeon Richter Mexico S.A.P.I. de C.V. has committed to a strong marketing plan for Gynofit and its success, which Easton / BMV and Gedeon Richter believe will steadily drive sales in Mexico over the next three years and beyond.
Other News
Easton Pharmaceuticals continues to move forward with its due diligence for the acquisition of revenue generating iBliss Inc., as previously announced and expects to have the transaction completed sometime in the month of February once all terms of the agreement have been agreed to and finalized.
Easton is also confirming that it has entered into negotiations towards acquiring a second revenue generating company possessing strong international sales which could coincide with the closing of iBliss and BMV Medica S.A.
Easton is also in late stage negotiations towards 2 (two) agreements with two 2 (two) medical marijuana companies, one in Jamaica and the other in the US, both expecting to potentially add significant and near term sales to Easton. Updates are expected this month or as they materialize.
Easton also confirms that late stage negotiations are continuing towards Eastons / BMV Medica's other licensed products (VS-Sense, AL-Sense). Detailed updates expected very shortly
For More Detailed Information On iBliss Visit: https://iblissvapor.com
For More Detailed Information on Gedeon Richter Plc Visit:
http://www.richter.hu/en-US/Pages/default.aspx
About Easton Pharmaceuticals
Easton Pharmaceuticals is a diversified specialty pharmaceutical company involved in various pharmaceutical sectors and other growing industries. The Company previously developed and owned an FDA-approved wound-healing drug and currently owns topically delivered drugs to treat cancer and other therapeutic products to treat various conditions that are all in various stages of development and approval. Easton has partnered with BMV Medica SA de C.V. and together, own the exclusive distribution rights in Mexico and Latin America for patented women's diagnostic and preventative care products from CommonSense of Israel, along with two generic cancer drugs, Paclitaxel and Docetaxel from BioLyse Pharma of St. Catherine's Ontario, Canada.
For More Information Visit: http://www.eastonpharmaceuticalsinc.com
http://www.bmvmedica.net
http://ecigmarkets.com
http://finance.yahoo.com/q?s=eaph
https://twitter.com/eastonpharma
Safe Harbor This news release may contain forward-looking statements or expressions within the meaning of the Private Securities Litigation Reform Act of 1995 (The "Act"). In particular, when certain words or phrases such as "hope", "positive", "anticipate," "pleased," "plan," "confident that," "believe," "expect," "possible" or "intent to" and similar conditional expressions are expressed, they are intended to identify forward-looking statements within the meaning of the Act and are subject to the safe harbor created by the Act. Such statements are subject to certain risks and uncertainties and actual results could differ materially from those expressed in any of the forward-looking statements. Such risks and uncertainties include, but are not limited to, market conditions, general acceptance of the company's products and technologies, competitive factors, the ability to successfully complete additional or adequate financing, government approvals or changes to proposed laws and other risks and uncertainties further stated in the company's financial reports and filings.
Contact Information
Evan Karras
CEO
Tel: +1(416) 619-0291
Tel: +1(347) 284-0192
Email: info@eastonpharmaceuticalsinc.com
Source: Easton Pharmaceuticals, Inc.
Info.
Lots of good news to come. Product launch in 10 days. Revenues have already started through the efforts of a multi-billion dollar pharmaceutical company ( Gedeon Richter).
They have setup meetings for the acquisition of a second revenue generating company.
They are receiving the last batch of documents from iBliss this week towards closing. Their sales are expanding rapidly.
Soon they will close on a JV distribution agreement with Bayer or Gedeon for the other two products.
Viele gute Nachrichten zu kommen. Produkteinführung in 10 Tagen. Die Einnahmen haben bereits durch die Bemühungen eines milliardenschweren Pharmaunternehmens (Gedeon Richter) begonnen.
Sie haben Setup-Meetings für den Erwerb eines zweiten Umsatz generierenden Unternehmens.
Sie erhalten die letzte Charge von Dokumenten von iBliss diese Woche in Richtung Schließung. Ihre Verkäufe wachsen schnell.
Bald werden sie auf einer JV-Vertriebsvereinbarung mit Bayer oder Gedeon für die beiden anderen Produkte schließen.
Haben jetzt jahre darauf gewartet bis was passiert langsam aber sicher bewegt sich hier was ,
leider noch nicht in deutschland handelbar und bei DB Maxblue gibt es probleme versuche einen broker zu finden der an der OTC-BB handeln kann vieleicht kennt jemand von euch einen.
Lots of good news to come. Product launch in 10 days. Revenues have already started through the efforts of a multi-billion dollar pharmaceutical company ( Gedeon Richter).
They have setup meetings for the acquisition of a second revenue generating company.
They are receiving the last batch of documents from iBliss this week towards closing. Their sales are expanding rapidly.
Soon they will close on a JV distribution agreement with Bayer or Gedeon for the other two products.
Viele gute Nachrichten zu kommen. Produkteinführung in 10 Tagen. Die Einnahmen haben bereits durch die Bemühungen eines milliardenschweren Pharmaunternehmens (Gedeon Richter) begonnen.
Sie haben Setup-Meetings für den Erwerb eines zweiten Umsatz generierenden Unternehmens.
Sie erhalten die letzte Charge von Dokumenten von iBliss diese Woche in Richtung Schließung. Ihre Verkäufe wachsen schnell.
Bald werden sie auf einer JV-Vertriebsvereinbarung mit Bayer oder Gedeon für die beiden anderen Produkte schließen.
Haben jetzt jahre darauf gewartet bis was passiert langsam aber sicher bewegt sich hier was ,
leider noch nicht in deutschland handelbar und bei DB Maxblue gibt es probleme versuche einen broker zu finden der an der OTC-BB handeln kann vieleicht kennt jemand von euch einen.
Info.
EAPH is LONG and STRONG:
Gideon Richter JV – done deal for Big Pharma multi
international sales and distribution of EAPH patented drugs.
AMFIL JV – consummated option for up to 49% ownership.
BMV Acquisition in late stages for 100% ownership.
Ibliss Acquisition in late stages for 100% ownership.
BAYER potential JV in late stages for second Big Pharma multi
international sales and distribution of EAPH patented drugs.
MMJ JV’s in Canada, US and Jamaica in late stages for
grower license, sales and distribution.
Other Cancer Drugs being worked into Big Pharma deals.
Was anything missed ? Go EAPHHHHHHHHHHHHH
EAPH ist LANGE und STARK:
Gideon Richter JV - abgeschlossener Auftrag für Big Pharma multi
Internationalen Verkauf und Vertrieb von EAPH patentierten Medikamenten.
AMFIL JV - vollzogene Option für bis zu 49% Eigentum.
BMV Akquisition in späten Phasen für 100% Besitz.
Ibliss Akquisition in späten Phasen für 100% Besitz.
BAYER Potenzial JV in den späten Stadien für die zweite Big Pharma Multi
Internationalen Verkauf und Vertrieb von EAPH patentierten Medikamenten.
MMJ JV's in Kanada, USA und Jamaika in späteren Stadien für
Erzeuger Lizenz, Vertrieb und Vertrieb.
Andere Krebs-Drogen, die in Big Pharma Abkommen gearbeitet werden.
War etwas verpasst? Gehen EAPHHHHHHHHHHHHH
EAPH is LONG and STRONG:
Gideon Richter JV – done deal for Big Pharma multi
international sales and distribution of EAPH patented drugs.
AMFIL JV – consummated option for up to 49% ownership.
BMV Acquisition in late stages for 100% ownership.
Ibliss Acquisition in late stages for 100% ownership.
BAYER potential JV in late stages for second Big Pharma multi
international sales and distribution of EAPH patented drugs.
MMJ JV’s in Canada, US and Jamaica in late stages for
grower license, sales and distribution.
Other Cancer Drugs being worked into Big Pharma deals.
Was anything missed ? Go EAPHHHHHHHHHHHHH
EAPH ist LANGE und STARK:
Gideon Richter JV - abgeschlossener Auftrag für Big Pharma multi
Internationalen Verkauf und Vertrieb von EAPH patentierten Medikamenten.
AMFIL JV - vollzogene Option für bis zu 49% Eigentum.
BMV Akquisition in späten Phasen für 100% Besitz.
Ibliss Akquisition in späten Phasen für 100% Besitz.
BAYER Potenzial JV in den späten Stadien für die zweite Big Pharma Multi
Internationalen Verkauf und Vertrieb von EAPH patentierten Medikamenten.
MMJ JV's in Kanada, USA und Jamaika in späteren Stadien für
Erzeuger Lizenz, Vertrieb und Vertrieb.
Andere Krebs-Drogen, die in Big Pharma Abkommen gearbeitet werden.
War etwas verpasst? Gehen EAPHHHHHHHHHHHHH
Info.
Big meeting this Wednesday in New York. Who do they have the meeting with, Bayer or Gedeon Richter. Whatever company it is it's a good deal and a deal to make millions of dollars in profits.
Big meeting this Wednesday in New York. Who do they have the meeting with, Bayer or Gedeon Richter. Whatever company it is it's a good deal and a deal to make millions of dollars in profits.
Easton Pharmaceuticals Begins Discussions to Acquire an Interest in an Operating Casino and Hotel Resort in Greece with Revenues in Excess of 60 Million Euro Per Year
TORONTO, ON, Aug. 22, 2018 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Easton Pharmaceuticals Inc. (OTC: EAPH) Announces that it has begun discussions to acquire an interest or participate in the acquisition of an operating casino and hotel resort in Greece. The resort comprises of a private beach, 255 rooms and 20 suites, 8 restaurants, a wellness center, conference facilities and an 87 table/1,000 slot machine casino plus a VIP area.
As part of its plan to enter more lucrative market segments, Easton has begun discussions with a company acquiring an operating casino/hotel resort property in Greece. This is one of just 9 casinos operating in Greece. Easton’s CEO, Mr. Evan Karras, participated in the privatization of gaming in Greece in the 1990’s, has nurtured strong relationships and is familiar with the property and the gaming industry in the country. “This casino was one of the most successful casinos in Europe when it opened, and I am excited for the prospects of having Easton participate in such an incredible opportunity” stated Mr. Evan Karras. Mr. Karras further commented “This Agreement is one of several that Easton is looking to enter into for gaming globally and would bring the Company and its shareholders tremendous value and growth”. Easton is negotiating its participation with the company acquiring the property. The acquisition is at a substantial discount of its cost with Easton assembling a specialized gaming team to manage the property. The property offers substantial upside, both in the gaming sector, as well as the hospitality sector and along with redevelopment potential for luxury managed condominium vacation units.
The discussions are currently highly confidential and anticipated to be completed this month or shortly thereafter with additional detailed information to be provided in the coming days or as it becomes readily available and approved for release.
TORONTO, ON, Aug. 22, 2018 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Easton Pharmaceuticals Inc. (OTC: EAPH) Announces that it has begun discussions to acquire an interest or participate in the acquisition of an operating casino and hotel resort in Greece. The resort comprises of a private beach, 255 rooms and 20 suites, 8 restaurants, a wellness center, conference facilities and an 87 table/1,000 slot machine casino plus a VIP area.
As part of its plan to enter more lucrative market segments, Easton has begun discussions with a company acquiring an operating casino/hotel resort property in Greece. This is one of just 9 casinos operating in Greece. Easton’s CEO, Mr. Evan Karras, participated in the privatization of gaming in Greece in the 1990’s, has nurtured strong relationships and is familiar with the property and the gaming industry in the country. “This casino was one of the most successful casinos in Europe when it opened, and I am excited for the prospects of having Easton participate in such an incredible opportunity” stated Mr. Evan Karras. Mr. Karras further commented “This Agreement is one of several that Easton is looking to enter into for gaming globally and would bring the Company and its shareholders tremendous value and growth”. Easton is negotiating its participation with the company acquiring the property. The acquisition is at a substantial discount of its cost with Easton assembling a specialized gaming team to manage the property. The property offers substantial upside, both in the gaming sector, as well as the hospitality sector and along with redevelopment potential for luxury managed condominium vacation units.
The discussions are currently highly confidential and anticipated to be completed this month or shortly thereafter with additional detailed information to be provided in the coming days or as it becomes readily available and approved for release.
Beitrag zu dieser Diskussion schreiben
Zu dieser Diskussion können keine Beiträge mehr verfasst werden, da der letzte Beitrag vor mehr als zwei Jahren verfasst wurde und die Diskussion daraufhin archiviert wurde.
Bitte wenden Sie sich an feedback@wallstreet-online.de und erfragen Sie die Reaktivierung der Diskussion oder starten Sie eine neue Diskussion.
Investoren beobachten auch:
Wertpapier | Perf. % |
---|---|
-0,12 | |
+1,92 | |
+0,53 | |
+0,88 | |
+0,78 | |
-4,39 | |
-4,56 | |
+0,63 | |
+0,21 | |
+16,08 |
Meistdiskutiert
Wertpapier | Beiträge | |
---|---|---|
111 | ||
69 | ||
45 | ||
40 | ||
39 | ||
38 | ||
37 | ||
36 | ||
35 | ||
33 |